Assess Before You Invest
Applied BioMath Assess is an interactive, web-based application that helps assess the difficulties and risks in developing a therapeutic very early-on. With Applied BioMath Assess, you can:
- Gain Insight with Built-in Analyses and Interactive Plots
- Get Started Quickly with Pre-built Pharmacology Models
- Easily Explore "What If" Questions with Scenarios
- Document, Share, and Reproduce Your Analyses
Please view our short case study videos:
Helping You Answer the Tough Questions
How hard will it be to develop the biologic (e.g., affinity, avidity, format, T1/2, dose, dose frequency, uncertainty)?
What are the pros and cons of targeting the ligand or receptor?
Should I expect Target Mediated Drug Disposition (TMDD) with this target?
Do I already have my Lead(s) or do I need to continue optimizing?
How likely is it that my dose will be too high for High Concentration Liquid Formulation?
Can my bispecific be differentiated from fixed dose combinations of monospecific antibodies?
Do I need to worry about soluble receptors for this target?
Should I expect improved affinity or PK to translate to improved dosing?
How do I think about Therapeutic Index (TI) in the design of the therapy?
Why Should I Use Applied BioMath Assess?
Applied BioMath Assess is an intuitive, interactive application that will help you and your team:
- Identify what drug parameters are required
- Identify what biological parameters are important
- De-risk a project by highlighting challenges early-on
- Determine what experiments are most important
Who Benefits From Using Applied BioMath Assess?
Applied BioMath Assess is most useful in early R&D stages for:
- Project Leaders
- Protein Engineers & Chemists
Virtual office hours are held every Tuesday and Thursday, 12PM, US EST. Please feel free to join if you have any questions about using Applied BioMath Assess or if you'd like to see a demo!
Visit our Assess documentation portal for product documentation as well as video case studies.
Gain Deeper Insight with Built-in Analyses and Interactive Plots
Perform 1- or 2-dimensional scans by simply selecting scan parameters and output feasibility criteria including percent inhibition, activation, and target engagement. Visually assess results and key parameter values by interacting with dose-response and pharmacokinetic and pharmacodynamic (PK/PD) plots.
Get Started Quickly with Pre-built Pharmacology Models
Choose from a library of monospecific and bispecific, single compartment and multiple compartment models covering most common pharmacologies. Add-on options include T-cell engager models, biotherapeutic models with avidity, and custom models.
Easily Explore “What If” Questions with Scenarios
Create Scenarios, or sets of parameters, to easily contrast and compare various scenarios. Add, duplicate, or delete scenarios with the click of a button in the Applied BioMath Assess interface. Vary parameters in the scenario table to explore risk and uncertainty while high-performance computing supports near real-time simulation when any scenario is selected.
Document, Share, and Reproduce Your Analyses
Save scenario sets for traceability and reproducibility and/or to share work with your colleagues. Automatically generate a PDF report with a unique ID and date and time stamp and download plots individually as PNG images.
"Applied BioMath Assess enables me to quickly explore design hypotheses, and better understand tradeoffs between PK, Target Engagement, and TMDD of our bispecific antibodies. To be able to explore these variables in an interactive tool without having to program it from scratch is an immense time and resource saver for me. This is a powerful tool put directly in the hands of scientists."
Applied BioMath Assess was an essential step for our portfolio prioritization. We had several therapeutics under consideration and needed to understand what parameter ranges were required to achieve our desired outcomes. Being able to quickly analyze each therapeutic helped us identify which therapeutics were best to pursue and ultimately helped us de-risk our portfolio and provide a clear and scientific rationale with our stakeholders."
David de Graaf
Co-Founder, Tuned Therapeutics